Randomized Salvage Therapy with Saquinavir-Ritonavir versus Saquinavir-Nelfinavir for Highly Protease Inhibitor-Experienced HIV-Infected Patients

REFERENCES

• Deeks S, Hecht F, Swanson M. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic. AIDS. 1999;13:F35–F43.
   PubMed Web of Science ®Google Scholar
• Girard P, Guiguet M, Bollens D, et al., and the Triest Cohort Investigators. Long-term outcome and treatment modifica-tions in a prospective cohort of human immunodeficiency virus type 1 infected patients on triple-drug antiretroviral regimens. Clin Infect Dis. 2000;31:987–994.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Youle M, Moore A, et al. Reasons for modifica-tion and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS. 200115: 185–194.
   Google Scholar
• Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults. Updated recommendations of the Inter-national AIDS Society-USA panel. JAMA. 2000;283:381–390.
   PubMed Web of Science ®Google Scholar
• Deeks S, Hellman N, Grant R. Novel four-drug salvage treatment regimens after failure of a human immunodefi-ciency virus type 1 protease inhibitor-containing regimen. J Infect Dis. 1999;179:1375–1381.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Phillips A, Miller V, et al., EuroSida Study Group. The use of and response to second-line protease inhibitor regimens: Results from the EuroSIDA study. AIDS. 2001;15:201–209.
   PubMed Web of Science ®Google Scholar
• Garaffo R, Durant J, Clevenbergh P. Relevance of protease inhibitor plasma levels in patients treated with genotypic adapted therapy [abstract]. Antiviral Ther. 1999;4\(Suppl 1):75. Abstract 109.
   PubMed Web of Science ®Google Scholar
• Havlir D, Hellmann N, Petropoulos C, et al. Drug suscepti-bility in HIV infection after viral rebound in patients receiv-ing indinavir-containing regimens. JAMA. 2000;283:229–234.
   PubMed Web of Science ®Google Scholar
• Hirsch M, Brun-Vezinet F, D'Aquila R, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. Recom-mendation of an International AIDS Society-USA panel. JAMA. 2000;283:2417–2426.
   PubMed Web of Science ®Google Scholar
• Lorenzi P, Opravil M, Hirschel B. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS. 1999;13:F17–F21.
   PubMed Web of Science ®Google Scholar
• Zolopa A, Schafer R, Warlord A. HIV-1 genotypic resis-tance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy has failed. Ann Intern Med. 1999;131(11):813–821.
   PubMed Web of Science ®Google Scholar
• Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergo-ing combination therapy: Survey of 787 sequences. J Clin Microbiol. 1999;37:4099–4106.
   PubMed Web of Science ®Google Scholar
• Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135–1141.
   PubMed Web of Science ®Google Scholar
• Tremblay C, Merrill D, Chou T, Hirsch M. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 iso-lates. J Acquir Immune Defic Syndr. 1999;22:430–436.
   PubMed Web of Science ®Google Scholar
• Nascimbeni M, Lamotte C, Peytavin G, Farinotti R, Clavel F. Kinetics of antiviral activity and intracellular pharmacoki-netics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob Agents Chemother. 1999;43:2629–2634.
   PubMed Web of Science ®Google Scholar
• Kempf D, Marsh K, Kumar G, et al. Pharmacokinetic en-hancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;71:654–660.
   Web of Science ®Google Scholar
• Rockstroh J, Altfeld M, Kupfer B, et al. Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy. Eur J Med Res. 1999;4:271–274.
   PubMedGoogle Scholar
• Rodriguez-Rosado R, Soriano V, Barreiro P, Dona C, Gonzalez-Lahoz J. What dual protease inhibitor combina-tion for salvage therapies? AIDS. 1999;13:2180–2181.
   Google Scholar
• Hoffmann F, Notheis G, Wintergerst U, Eberle J, Glitter L, Belohradsky B. Comparison of ritonavir plus saquinavir and nelfinavir plus saquinavir-containing regimens as sal-vage therapy in children with human immunodeficiency type 1 infection. Pediatr Infect Dis J. 2000;19:47–51.
   PubMed Web of Science ®Google Scholar
• Kirk O, Katzenstein T, Gerstoft J, et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial. AIDS. 1999;13:F9–F16.
   PubMed Web of Science ®Google Scholar
• Tebas P, Patick A, Kane F, et al. Virologic responses to a ritonavir-saquinavir-containing regimen in patients who previously failed nelfinavir. AIDS. 1999;13:F23–F28.
   PubMed Web of Science ®Google Scholar
• Moyle G, Pozniak A, Opravil M, et al. The SPICE Study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. J Acquir Immune Defic Syndr. 2000;23:128–137.
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradat Study. AIDS. 2000;14:1333–1339.
   PubMed Web of Science ®Google Scholar
• Cozzi Lepri A, Miller V, Phillips A, Rabenau H, Sabin C, Staszewski S. The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load. AIDS. 2001;15:47–54.
   PubMed Web of Science ®Google Scholar
• Montaner J, Harrigan P, Jahnke N, et al. Multiple drug rescue therapy for HIV-infected individuals with prior viro-logic failure to multiple regimens. AIDS. 200115: 61–69.
   Google Scholar
• Paredes R, Puig Y, Arno A, et al. High-dose saquinavir plus ritonavir: Long term efficacy in HIV-positive protease in-hibitor-experienced patient(s) and predictors of virologic response. J Acquir Immune Defic Syndr. 1999;22:194–195.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Devereux H, Kinloch-de-Loes S, et al., Royal Free Centre for HIV Medicine. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS. 2000;14:1545–1552.
   PubMed Web of Science ®Google Scholar
• Piroth L, Grappin M, Weidner A, et al. Discontinuation of protease inhibitors due to intolerance: A longitudinal study of 309 HIV-1 positive patients. La Presse Médicale. 1999;28:381–387.
   PubMed Web of Science ®Google Scholar